Pharmacologic and Therapeutic Differences Among Calcium Channel Antagonists: Profile of Mibefradil, a New Calcium Antagonist
- 1 November 1996
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 78 (9) , 7-12
- https://doi.org/10.1016/s0002-9149(96)00732-1
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Calcium channel diversity in the cardiovascular systemJournal of the American College of Cardiology, 1996
- Calcium Antagonists Should Continue to Be Used for First-Line Treatment of HypertensionArchives of internal medicine (1960), 1995
- Selective inhibition of T-type Ca2+ channels by Ro 40-5967.Circulation Research, 1994
- Cardiovascular Profile of Ro 40–5967, a New Nondihydropyridine Calcium Antagonist, Delineated in Isolated, Blood-Perfused Dog HeartsJournal of Cardiovascular Pharmacology, 1993
- Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprololThe American Journal of Cardiology, 1993
- Selectivity Scale of Calcium Antagonists in the Human Cardiovascular System Based on In Vitro StudiesJournal of Cardiovascular Pharmacology, 1992
- In Vitro Pharmacologic Profile of Ro 40-5967, a Novel Ca2+ Channel Blocker with Potent Vasodilator but Weak Inotropic ActionJournal of Cardiovascular Pharmacology, 1989
- DILTIAZEM AND HEART BLOCKThe Lancet, 1989
- Classes of Calcium Channels in Vertebrate CellsAnnual Review of Physiology, 1989
- Transfer of Nimodipine and Another Calcium Antagonist Across the Blood-Brain Barrier and Their Regional Distribution In VivoPublished by Springer Nature ,1989